Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution

• Published in: Cancers Vol. 13; no. 15; p. 3900
• Main Authors: Rivero, Andrea, Mozas, Pablo, Jiménez, Laura, López-Guerra, Mónica, Colomer, Dolors, Bataller, Alex, Correa, Juan, Rivas-Delgado, Alfredo, Bastidas, Gabriela, Baumann, Tycho, Martínez-Trillos, Alejandra, Delgado, Julio, Giné, Eva, Campo, Elías, López-Guillermo, Armando, Villamor, Neus, Magnano, Laura, Matutes, Estella
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.08.2021; MDPI
• Subjects: Anemia; Apoptosis; Asymptomatic; Autoimmune diseases; Biopsy; Blood; Bone marrow; CD4 antigen; CD57 antigen; CD8 antigen; chronic lymphoproliferative disorder of NK cells; Cytotoxicity; Flow cytometry; Genotype & phenotype; Hematological diseases; Hematology; Infections; Leukemia; Lymphatic leukemia; Lymphocytes; Lymphocytes T; Methotrexate; Morphology; Mutation; Natural killer cells; Neutropenia; outcome; Patients; Solid tumors; STAT3; Stat3 protein; Survival analysis; T-cell large granular lymphocytic leukemia; Thrombocytopenia; T-cell large granular lymphocytic leukemia; chronic lymphoproliferative disorder of NK cells; outcome; STAT3
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13153900

T-cell large granular lymphocytic leukemia (T-LGLL) and chronic lymphoproliferative disorder of natural killer (NK) cells are two infrequent diseases characterized by clonal expansions of cytotoxic T lymphocytes and NK cells, respectively. Somatic mutations of are involved in the pathogenesis of these entities. We describe the clinicobiological features, mutational status of , treatment and outcome of 131 patients. Neutropenia was the most frequent finding at diagnosis, followed by anemia. Concurrent hematological disorders were diagnosed in 37% of patients and autoimmune conditions and solid tumors in 17% and 15%, respectively. All patients who needed treatment belonged to the CD8 CD57 group. Remarkably, patients included in the CD4 group had a higher association with solid tumors ( = 0.037). mutations were found in 17% of patients, mainly Y640F and D661Y mutations. Patients carrying mutations more frequently presented with anemia, neutropenia, high LDH, high large granular lymphocyte counts and need for treatment ( = 0.0037). Methotrexate was the most frequently used agent (72% of cases). The overall response rate to all treatments was 50%. The 10-year overall survival of this series was 78%, with no differences according to the mutational status of . We compared the survival of these patients with the general Spanish population and no differences were found, confirming the indolent nature of these hematological malignancies. Our study further extends findings documented by others on the clinical behavior of the disease and the impact of , and for the first time analyzes survival compared to a matched general Spanish population.